Esther Cho
CIK: 0002081460
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Keros Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 18, 2026KROS
Keros Therapeutics, Inc.
Sale(S)Direct4.5K shares at avg. $10.29$46K - Feb 24, 2026KROS
Keros Therapeutics, Inc.
Award(A)DirectEmployee Stock Option (Right to Buy)
80K shares- - Feb 24, 2026KROS
Keros Therapeutics, Inc.
Award(A)DirectEmployee Stock Option (Right to Buy)
80K shares- - Feb 18, 2026KROS
Keros Therapeutics, Inc.
Sale(S)Direct4.7K shares at avg. $16.35$78K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 | KROS Keros Therapeutics, Inc. | Sale(S) | 4,485 | $10.29 | $46,151 | Direct |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | Award(A) Employee Stock Option (Right to Buy) | 80,000 | - | - | Direct |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | Award(A) Employee Stock Option (Right to Buy) | 80,000 | - | - | Direct |
| Feb 18, 2026 | KROS Keros Therapeutics, Inc. | Sale(S) | 4,745 | $16.35 | $77,581 | Direct |
1-4 of 4 transactions
About Cho Esther
Cho Esther (SEC CIK 0002081460) files insider reports with the SEC as Chief Legal Officer of Keros Therapeutics, Inc. (KROS).
Signal8 holds 5 ownership filings by Cho Esther (1 Form 3, 4 Form 4), filed between Aug 15, 2025 and Aug 20, 2026. Those filings report 4 transactions, from Feb 18, 2026 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cho Esther's filings is in LEXINGTON, MA.
Recent filings by Cho Esther
Other insiders filing for Keros Therapeutics, Inc. (KROS)
- Tanini Annita, Corp. Controller & VP, Finance
- Lerner Lorena Raquel, Chief Scientific Officer
- Newton Charles W., Director
- BIENAIME JEAN JACQUES, Director
- Prener Anne, Director
- Farzan Nima, Director